Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 2/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11024134 | 1.00 | GAA (0.46) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6231243 | 0.93 | GBA1 (0.53) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6235119 | 0.93 | GBA1 (0.53) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6232582 | 0.93 | GBA1 (0.53) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6233396 | 0.88 | KDM4E (0.36) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6234245 | 0.79 | L3MBTL1 (0.39) | — | |
| SCHEMBL27082357 | 0.78 | GAA (0.47) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL1363459 | 0.77 | GAA (0.46) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL27082407 | 0.77 | GAA (0.46) | GAATP53GBA1ABL1RIN1 | |
| SCHEMBL6235193 | 0.76 | GAA (0.44) | GAATP53GBA1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4647574-A | Hypoglycemic hydantoin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-03-03 | — | — | US | claimed |
| EP-0160618-A1 | Hydantoin derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1985-11-06 | — | — | EP | claimed |
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110740729-B | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2023-05-16 | — | — | CN | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | NATIONAL CANCER CENTER (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3639821-A1 | CARCINOGENESIS INHIBITOR | National Cancer Center (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| CN-1197572-C | Hypoalbuminemia improvement agent | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-20 | — | — | CN | disclosed |
| CN-1143674-C | Refractory vasculitis therapeutic preparation | �ձ���ҩ��ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| EP-1018339-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| CN-1253775-A | Refractory vasculitis therapeutic preparation | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-05-24 | — | — | CN | disclosed |
| CN-1159324-A | Active oxygen, free radical scavenger | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 1997-09-17 | — | — | CN | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0160618-B1 | HYDANTOIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4647574-A | Hypoglycemic hydantoin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-03-03 | — | — | US | disclosed |
| EP-0160618-A1 | Hydantoin derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1985-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | GAA 3618/4885TP53 24/4885GBA1 4631/4885 |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | APC, MKI67, HRAS | GAA 3618/4885TP53 24/4885GBA1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.